Clinical and microbiological profile of adult inpatients with community acquired pneumonia in Ilorin, North Central, Nigeria

Olutobi Babatope Ojuawo1, Olufemi Olumuyiwa Desalu1, Ademola Emmanuel Fawibe1, Ayotade Boluwatife Ojuawo2, Adeniyi Olatunji Aladesanmi1, Christopher Muyiwa Opeyemi1, Mosunmoluwa Obafemi Adio1, Abdulraheem Olayemi Jimoh1, Dele Ohinoyi Amadu1, Abayomi Fadyi3, Kazeem Alakija Salami1

1. Department of Medicine, University of Ilorin Teaching Hospital, Ilorin, Nigeria.
2. Department of Paediatrics, University of Ilorin Teaching Hospital, Ilorin, Nigeria.
3. Department of Medical Microbiology, University of Ilorin Teaching Hospital, Ilorin, Nigeria.

Abstract
Background: The optimal management of community acquired pneumonia (CAP) depends on the clinical and microbiological profile in the locality.
Objectives: To determine the clinical and microbiological profile of patients admitted with CAP in Ilorin, Nigeria.
Methods: One hundred and two consenting consecutively selected patients with clinical and radiologic confirmation of CAP were recruited in 12 months. The socio-demographic, physical examination and laboratory/radiologic parameters were documented in a questionnaire. Microbiological evaluation of their sputum was done and blood samples were taken for complete blood count, culture, serum urea and serological evaluation for atypical bacteria and some viral pathogens.
Results: CAP constituted 5.9% of the total medical admissions during the one-year study period. The mean age of the patients was 49 ± 22 years with the largest frequency in those aged 65 years and above. The commonest symptoms were shortness of breath (96.1%) and cough (94.1%), with a median duration of 3 days from symptom onset to admission. Systemic hypertension was the commonest comorbid illness (25/102; 24.5%). Klebsiella pneumoniae was the predominant pathogen isolated (20/102; 28.1%). The susceptible antibiotics were Imipenem, Ceftazidime and Ceftriaxone. Intra-hospital mortality was 17.6%. CURB – 65 score of ≥ 2 and the presence of complications of CAP were the independent predictors of mortality.
Conclusion: CAP constitutes a significant disease burden in Ilorin, Nigeria. Typical bacteria accounted for over half of the pathogens isolated from the patients with gram negative agents predominating. This highlights a possible shift in the microbiological profile which could guide empirical treatment.

Keywords: Community acquired pneumonia; microbiological profile; Nigeria.
DOI: https://dx.doi.org/10.4314/ahs.v20i4.18
Cite as: Ojuawo OB, Desalu OO, Fawibe AE, Ojuawo AB, Aladesanmi AO, Opeyemi CM, et al. Clinical and microbiological profile of adult inpatients with community acquired pneumonia in Ilorin, North Central, Nigeria. Afri Health Sci. 2020;20(4):1655-68. https://dx.doi.org/10.4314/ahs.v20i4.18

Introduction
Community acquired pneumonia (CAP) is associated with a significant burden of disease globally; accounting for a significant number of hospital admissions and deaths especially in low income. The disease is prevalent in Nigeria and is responsible for 2.5% - 5.7% of the medical admissions; as well as between 15.3 and 24.9% of respiratory admission from previous studies in tertiary health facilities in the country. The mortality from previous surveys concerning admitted patients with CAP in the country also ranged from 7.4% to 26%. Epidemiological reports from sub Saharan Africa also show high levels of morbidity and mortality from the disease as approximately 4 million cases of pneumonia occur annually, resulting in about 200,000 deaths. Globally, about 450 million people are estimated to be affected with pneumonia every year; accounting for about 7% of the world's deaths.

Corresponding author:
Olutobi Babatope Ojuawo,
Pulmonology Unit,
Department of Medicine,
University of Ilorin Teaching Hospital, Ilorin.
Telephone: +2348034490267
Email address: obk_ojuawo@yahoo.com
Despite the availability of antimicrobial agents and effective vaccines, the disease also constitutes the sixth leading cause of death in the United States of America and the number one cause of death from infectious diseases. The increasing burden of the disease has been linked to the high prevalence of specific risk factors for this infection in patients worldwide. This occurs, mainly, from immunosuppressive illnesses like human immunodeficiency virus (HIV) infection and diabetes mellitus as well as structural lung diseases like chronic obstructive pulmonary disease (COPD), bronchiectasis and cystic fibrosis.

Regarding the microbiological profile, Streptococcus pneumoniae was the most frequent isolate in previous studies in the SouthEast and South-South regions of Nigeria. However, Klebsiella pneumoniae was the commonest pathogen in other studies in the middle belt and South Western regions of the country. These surveys however did not evaluate presence of atypical bacterial and viral pathogens.

Generally, the morbidity and mortality associated with CAP is related to the disease severity at presentation, presence of co-morbid illness and delays in starting appropriate drug therapy. Despite the upsurge of antimicrobial resistance, the mortality associated with the disease can still be significantly mitigated by prompt institution of appropriate therapeutic medications. Hence, there is a need for information concerning the pattern of presentation, severity, prognostic factors, microbiological profile of pathogens causing CAP in our locality as well as identifying drug susceptibility with the goal of guiding prompt initiation of proper empirical treatment. There is also a paucity of information regarding the common atypical bacterial and viral pathogens causing CAP in our setting despite several previous reports on the disease.

Materials and methods

Study Location

This was a hospital based prospective observational study carried out in the emergency unit and adult medical wards of the University of Ilorin Teaching Hospital, Ilorin, Nigeria. The hospital is a 600-bed tertiary healthcare facility in North Central Nigeria and serves as a referral centre for patients in Kwara state as well as other adjoining states.

Patients

One hundred and two consenting patients with CAP who met the inclusion criteria for the study were recruited consecutively over a one-year period (January – December 2017). The patients recruited were individuals who had new onset of at least two of the respiratory symptoms of cough with or without sputum production, shortness of breath, chest pain and fever. All of them also had evidence of an infiltrate or opacity on plain chest x-ray. Seventy-four patients who had previously been admitted in a healthcare facility in the preceding 14 days prior to onset of current respiratory symptoms were excluded based on the definition of CAP as well as those who had taken any antibiotic before presentation. Only two patients did not give consent to participate in the study. Recruited patients were followed up from the time of admission to the outcome (discharge or death).

Data collection and procedures

A structured questionnaire adapted as a modification of the modified Medical Research Council respiratory questionnaire was administered to obtain the patient’s demographics and reported symptoms of CAP. A thorough physical examination was also carried out on all recruited subjects. Oxygen saturation at admission was measured on room air using a portable pulse oximeter (New Healthcare Finger Pulse Oximeter, China 2015). The blood pressure (BP) was measured with a mercury sphygmomanometer (Accosson, England) with standard cuff (25cm x 12cm) in supine position on both arms after at least 5 minutes’ rest. Two consecutive measurements were obtained about 5 minutes apart and the average was recorded.

A fifteen-milliliter sample of each patient’s venous blood was obtained by venipuncture at admission using a vacutainer under aseptic technique prior to commencement of first dose of empirical antibiotic(s). The blood sample was used for complete blood count, culture, serum urea as well as serological evaluation for Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella pneumophila, Influenza A virus and Respiratory syncytial virus (RSV). Serological evaluation for atypical bacterial and viral pathogens was carried out based on Enzyme Linked Immunosorbent Assay (ELISA) techniques, adhering strictly to the manufacturer’s instructions.

Sputum samples were also collected in sterile containers within the first hour of hospital admission in all the individuals who had productive cough. This was done in all recruited patients prior to commencement of the first dose of empirical antibiotics. The subjects were instructed to take deep breaths and cough forcefully from the lungs with expectoration of at least two mil-
litrnes of sputum. Collected sputum samples were first inspected macroscopically at the microbiology unit and then under a microscope. This was followed by initial gram staining after which culture was performed if the sputum specimen contained at least 25 neutrophils and less than 10 epithelial cells per high power field. Sputum samples were subsequently liquefied and inoculated into blood, MacConkey and chocolate agar. Thereafter, incubation was done aerobically at 37 degrees Celsius. The blood agar was for isolating *Streptococcus pneumoniae* and *Staphylococcus aureus*, MacConkey agar for Gram negative bacteria like *Klebsiella* species while the chocolate agar was used for isolating fastidious pathogens like *Haemophilus influenzae*. Drug sensitivity testing was done using disc diffusion methods using commonly available antibiotics.

Venous blood (5 millilitres) was inoculated into the brain heart infusion (BHI) broth containing 0.05% sodium polyanetholesulfonate. A minimum of blood to broth ratio of 1:10 was used. This was incubated at 37°C and checked for bacterial growth for up to 7 days. Bottles that showed growth were sub-cultured onto chocolate and MacConkey agar plates. Those with no growth after 7 days were sub-cultured before being labelled negative. The complete blood counts were carried out to obtain the white cell counts using an automated hematology analyzer. The serum urea levels were also assayed. HIV screening was also done after pre-test counselling. The severity of the disease was assessed at admission using the British Thoracic Society (BTS) recommended CURB-65 scoring method.

Data Analysis
All data obtained were analyzed using a statistical package for social science, IBM SPSS statistics® 2012 version 21.0 for Windows by IBM USA. Demographic and clinical data of cases were summarized using frequencies, percentages and proportions. Normally distributed continuous variables were expressed as means + standard deviations. Chi-square test was used to determine the relationship between the categorical variables. Multivariate binary logistic regression analysis was used to determine the predictors of intrahospital mortality.

Ethical issues
The study was approved by the Ethical Review Committee of the University of Ilorin Teaching Hospital, Ilorin, Nigeria. Informed consent was obtained from all patients prior to recruitment into the study.

Results
**Admission breakdown and socio-demographic characteristics of the study population**
One hundred and seventy-eight patients were admitted with pneumonia over the study period; 42 of them were excluded due to previous recent hospital admissions. This made the total number of CAP admissions to be 136. The hospital admissions for CAP within the study period constituted 5.9% (136/2297) of the total medical admissions. Thirty-two of the patients with CAP were excluded due to prior antibiotic use following while 2 did not consent to participate in the study. Eventually, 102 patients were recruited consisting 46 males and 56 females giving a male to female ratio of 1:1.2 (Table 1). The highest frequency in terms of the age group was observed in those aged 65 years and above (34/102; 33.3%). Ninety-five (93.1%) were managed on the medical ward while 7/102 (6.9%) required admission in the Intensive Care Unit (ICU). The months of June, July and August had the largest number of recruited patients with 14, 13 and 16 subjects respectively. (Table 2)
### Table 1: Socio-demographic characteristics of recruited subjects

| Socio-demographic variables         | Frequency (%) |
|------------------------------------|---------------|
|                                    | (n = 102)     |
| **Age group (in years)**           |               |
| ≤20                                | 12 (11.8)     |
| 21- 30                             | 15 (14.7)     |
| 31- 40                             | 17 (16.7)     |
| 41- 50                             | 8 (7.8)       |
| 51- 60                             | 12 (11.8)     |
| 61- 64                             | 5 (4.9)       |
| ≥ 65                               | 34 (33.3)     |
| **Mean Age:** 49.8 ± 22.1 years    |               |
| **Sex**                            |               |
| Male                               | 46 (45.1)     |
| Female                             | 56 (54.9)     |
| **Ethnic Group**                   |               |
| Yoruba                             | 98 (96.1)     |
| Hausa                              | 3 (2.9)       |
| Igbo                               | 1 (1.0)       |
| **Marital Status**                 |               |
| Single                             | 21 (20.6)     |
| Married                            | 67 (65.7)     |
| Widowed                            | 14 (13.7)     |

### Table 2: Monthly breakdown of patients recruited

| Month    | Frequency (%) |
|----------|---------------|
| January  | 5 (4.9)       |
| February | 7 (6.9)       |
| March    | 7 (6.9)       |
| April    | 8 (7.8)       |
| May      | 8 (7.8)       |
| June     | 14 (13.7)     |
| July     | 13 (12.7)     |
| August   | 16 (15.7)     |
| September| 7 (6.9)       |
| October  | 7 (6.9)       |
| November | 5 (4.9)       |
| December | 5 (4.9)       |
| **Total**| 102 (100)     |
Comorbid illnesses / risk factors for CAP
Systemic hypertension was the commonest comorbidity with almost a quarter (25; 24.5%) of the subjects affected. This was followed by diabetes mellitus and cigarette smoking in 11(10.8%) each of the patients respectively. Sickle cell disease was also a co-morbid illness/risk factor in 10 (9.8%) of the subjects. Fourteen (13.7%) of them had no co-morbid illness or risk factor for CAP. (Table 3)

| Co-morbidities/risk factors               | Frequency (%) |
|------------------------------------------|---------------|
| Systemic Hypertension                    | 25 (24.5)     |
| Diabetes Mellitus                        | 11 (10.8)     |
| Acid Peptic Disease                      | 6 (5.9)       |
| Connective Tissue Diseases               | 2 (2.0)       |
| Bronchial Asthma                         | 3 (2.9)       |
| Cigarette Smoking                        | 11 (10.8)     |
| Alcohol Ingestion                        | 3 (2.9)       |
| COPD                                     | 7 (6.9)       |
| Congestive Cardiac Failure               | 1 (1.0)       |
| Cancer                                   | 3 (2.9)       |
| HIV                                      | 6 (5.9)       |
| Sickle cell disease                      | 10 (9.8)      |
| No comorbidity/risk factor               | 14 (13.7)     |

Table 3: Frequencies of co-morbidities/risk factors for CAP

Presenting symptoms of recruited subjects
Shortness of breath was the commonest symptom reported by the patients, occurring in 98 (96.1%) of them. This was followed in a descending order by cough (94.1%), fever (89.2%), sputum production (84.3%) and pleuritic chest pain (41.2%). The median duration from onset of symptoms to hospital admission was 3 days (IQR of 2-7 days).

Classes of pathogens isolated
There was microbiological confirmation of CAP in 71 (69.6%) patients. Most of the pathogens isolated were typical bacterial pathogens alone (33; 32.3%). Viral agents and atypical bacterial pathogens alone were isolated in 11.8% and 10.7% of the subjects respectively. Mixed or double pathogens were detected in 13.7% of the patients.

Pathogens and mode of isolation
Twenty-one (20.6%) pathogens were isolated through sputum culture alone, 11 (10.8%) pathogens were isolated through blood culture alone while 2 (2.0%) pathogens were isolated from both sputum and blood culture (Table 4). Overall, *Klebsiella pneumoniae* (14.7%) was the most common single isolate followed by RSV (11.8%). *Legionella pneumophila* was the most common single atypical bacteria isolated (7.8%).
### Table 4: Pathogens and mode of isolation

| Organisms and mode of isolation | Frequency (%) |
|---------------------------------|---------------|
| **Sputum Culture alone (n=21; 20.6%)** |               |
| Klebsiella pneumoniae           | 8 (7.8)       |
| Streptococcus pneumoniae        | 6 (5.9)       |
| Staphylococcus aureus           | 2 (2.0)       |
| Pseudomonas aeruginosa          | 2 (2.0)       |
| Klebsiella oxytoca              | 2 (2.0)       |
| Candida albicans                | 1 (1.0)       |
| **Blood Culture alone (n=11; 10.8%)** |               |
| Klebsiella pneumoniae           | 6 (5.9)       |
| Staphylococcus aureus           | 4 (3.9)       |
| Pseudomonas aeruginosa          | 1 (1.0)       |
| **Sputum and Blood Culture (n=2; 2%)** |               |
| Klebsiella pneumoniae           | 1 (1.0)       |
| Staphylococcus aureus           | 1 (1.0)       |
| **Serology alone (n=24; 23.5%)** |               |
| Legionella pneumophilia         | 8 (7.8)       |
| Mycoplasma pneumoniae           | 3 (2.9)       |
| RSV                             | 12 (11.8)     |
| Legionella pneumophilia and RSV (double pathogens from serology) | 1 (1.0)       |
| **Mixed/Double pathogens (Sputum and or blood culture + Serology)** |               |
| Typical bacteria isolated from blood culture in combination with atypical bacteria/viruses isolated from serology (n=3; 2.9%) |       |
| Staphylococcus aureus and Legionella pneumophilia | 1 (1.0)       |
| Staphylococcus aureus and RSV   | 2 (2.0)       |
| Typical bacteria isolated from sputum culture in combination with atypical bacteria/viruses isolated from serology (n=7; 6.9%) |       |
| Klebsiella pneumoniae and Legionella pneumophilia | 2 (2.0)       |
| Klebsiella pneumoniae and RSV   | 1 (1.0)       |
| Klebsiella oxytoca and Legionella pneumophilia | 1 (1.0)       |
| Staphylococcus aureus and Influenza A virus | 1 (1.0)       |
| Streptococcus pneumoniae and Influenza A virus | 1 (1.0)       |
| Streptococcus pneumoniae and RSV | 1 (1.0)       |
| Typical bacteria isolated from both sputum and blood culture in combination with atypical bacteria/viruses from serology (n=3; 2.9%) |       |
| Klebsiella pneumoniae and Chlamydia pneumoniae | 1 (1.0)       |
| Klebsiella pneumoniae and Legionella pneumophilia | 1 (1.0)       |
| Staphylococcus aureus and Legionella pneumophilia | 1 (1.0)       |

### Complications and markers of severity of CAP

Table 5 shows that in all, 67 complications of CAP were identified across 63 (61.8%) of the patients with the commonest being hypoxaemia (50.7%; 34/67). There was radiographic evidence of multilobe lung involvement and the presence of bacteremia in 29.4% and 15.7% of the patients respectively. The median WBC count was 9.35 x 10^9/L (IQR 6.78 – 15.20) and almost half (45.1%) demonstrated leukocytosis on complete blood count.
Table 5: Complications of CAP in recruited subjects

| Complication             | Frequency (%) |
|--------------------------|---------------|
| Hypoxaemia               | 34 (50.7)     |
| Parapneumonic effusion   | 9 (13.4)      |
| Empyema thoracis         | 4 (5.9)       |
| Sepsis                   | 16 (23.9)     |
| Lung Abscess             | 2 (3.0)       |
| Massive haemoptysis      | 2 (3.0)       |
| **Total**                | **67 (100)**  |

- Some patients had more than one complication

**Drug sensitivity pattern**

Sixteen (80%) of the 20 isolates of Klebsiella pneumoniae were sensitive to Imipenem while 13 (65%) each were sensitive to Ceftazidime and Ceftriaxone respectively (Table 6). However, the gram-positive pathogens isolated (*Staphylococcus aureus* and *Streptococcus pneumoniae*) were most sensitive to Amoxicillin/Clavulanic acid.

Table 6: Drug sensitivity pattern

|                      | Cipro | Ceftria | AmC | Gent | Ceftaz | Imi | Pip/Taz | Azith | Cefurox |
|----------------------|-------|---------|-----|------|--------|-----|---------|-------|---------|
| *Klebsiella pneumonia* (20) |       |         |     |      |        |     |         |       |         |
| *Staphylococcus aureus* (12) |     |         |     |      |        |     |         |       |         |
| *Streptococcus pneumonia* (8) |     |         |     |      |        |     |         |       |         |
| *Klebsiella oxytoca* (3)     |     |         |     |      |        |     |         |       |         |
| *Pseudomonas aeruginosa* (3) |     |         |     |      |        |     |         |       |         |

- **Cipro** – Ciprofloxacin, **Ceftria** – Ceftriaxone, **AmC** – Amoxicillin/Clavulanic acid, **Gent** – Gentamicin, **Ceftaz** – Ceftazidime, **Imi** – Imipenem, **Pip/Taz** – Piperacillin Tazobactam, **Azith** – Azithromycin, **Cefurox** – Cefuroxime, **NT** – Not tested.

**Predictors of mortality during admission period.**

About three-quarters of the patients were discharged while the percentage mortality was 17.6% (95% CI: 9.49 -25.78). Table 7 shows that the mean age of the patients who died during the admission period was significantly higher than those who survived the illness (60.65 ± 21.90 vs. 47.60 ± 21.66 years; p=0.026). Also, the proportion of patients with CURB-65 scores of greater than or equal to 2 was significantly higher in those who succumbed to the illness when compared to those that survived (p=<0.001). The percentage of patients with hypoxemia was also significantly higher in patients who died when compared with those who survived (p=<0.001).
Table 7: Relationship between clinical outcome of patients and their socio-demographic/clinical parameters.

| Parameter                        | Patients alive during admission period (%) | Mortalities during admission period (%) | Total | Test statistics | p-value |
|----------------------------------|-------------------------------------------|----------------------------------------|-------|-----------------|---------|
| Mean Age (years)                 | 47.60 ± 21.66                             | 60.65 ± 21.90                          |       | 0.640<sup>a</sup> | 0.026   |
| Sex                              |                                           |                                        |       |                 |         |
| Male                             | 35 (41.2)                                 | 11 (64.7)                              | 46 (45.1) | 3.168<sup>b</sup> | 0.075   |
| Female                           | 50 (58.2)                                 | 6 (35.3)                               | 56 (54.9) |                 |         |
| Body Mass Index                  |                                           |                                        |       |                 |         |
| Underweight                      | 8 (9.4)                                   | 2 (11.8)                               | 10 (9.8) | 1.882<sup>c</sup> | 0.597   |
| Normal                           | 56 (65.9)                                 | 8 (47.1)                               | 64 (62.7) |                 |         |
| Overweight                       | 19 (22.4)                                 | 1 (5.9)                                | 20 (19.6) |                 |         |
| Mild Obesity                     | 1 (1.1)                                   | 0 (0)                                  | 1 (0.9)  |                 |         |
| CURB-65 score                    |                                           |                                        |       |                 |         |
| 0-1                              | 53 (5.9)                                  | 2 (0)                                  | 55 (4.9) | 14.59<sup>c</sup> | <0.001  |
| ≥2                               | 32 (56.5)                                 | 15 (23.5)                              | 47 (51.0) |                 |         |
| Site of patient treatment        |                                           |                                        |       |                 |         |
| Wards                            | 81 (95.3)                                 | 14 (82.3)                              | 95 (93.1) | 3.712<sup>d</sup> | 0.089   |
| ICU                              | 4 (4.7)                                   | 3 (17.6)                               | 7 (6.9)  |                 |         |
| Presence of comorbidities        |                                           |                                        |       |                 |         |
| Yes                              | 32 (37.6)                                 | 4 (23.5)                               | 36 (35.3) | 1.236<sup>b</sup> | 0.266   |
| No                               | 53 (62.4)                                 | 13 (76.5)                              | 66 (64.7) |                 |         |
| SpO2 (%)                         |                                           |                                        |       |                 |         |
| ≤ 90                             | 21 (15.3)                                 | 13 (76.5)                              | 34 (33.3) | 17.082<sup>c</sup> | <0.001  |
| >90                              | 64 (75.3)                                 | 4 (3.9)                                | 68 (66.7) |                 |         |

a= independent student t-test; b = chi-square; c = yates corrected chi-square, d= fisher’s exact test

Likewise, as shown in Table 8, the proportion of patients with involvement of 2 or more lung lobes was also significantly greater in those that died when compared to patients that survived (p=0.020). The multivariate binary logistic regression analysis illustrated in Table 9 shows that CURB-65 score of ≥2 and the presence of complications of CAP were the identified independent predictors of mortality (p = 0.020 and 0.004 respectively).
**Table 8:** Relationship between clinical outcome of the patients and their laboratory/radiologic parameters.

| Parameter                        | Patients alive during admission period (%) | Mortalities during admission period (%) | Total | Test statistics | p-value |
|----------------------------------|-------------------------------------------|----------------------------------------|-------|-----------------|---------|
| **Presence of complications**    |                                           |                                        |       |                 |         |
| Yes                              | 63 (74.1)                                 | 0 (0)                                  | 63    | 32.954<sup>b</sup> | <0.001  |
| No                               | 22 (25.9)                                 | 17 (100)                               | 39    |                 |         |
| **Number of lung lobes affected**|                                           |                                        |       |                 |         |
| 1                                | 64 (75.2)                                 | 8 (47.1)                               | 72    | 5.440<sup>c</sup> | <0.020  |
| ≥2                               | 21 (24.7)                                 | 9 (52.9)                               | 30    |                 |         |
| **Presence of bacteraemia**      |                                           |                                        |       |                 |         |
| Yes                              | 12 (14.1)                                 | 4 (23.5)                               | 16    | 0.949<sup>b</sup> | 0.330   |
| No                               | 73 (85.9)                                 | 13 (76.5)                              | 86    |                 |         |
| **WBC count (x10¹⁹/L)**          |                                           |                                        |       |                 |         |
| < 4 and >30                      | 8 (9.4)                                   | 1 (5.9)                                | 9     | 0.219<sup>b</sup> | 0.639   |
| 4 - 30                           | 77 (90.6)                                 | 16 (94.1)                              | 93    |                 |         |
| **Isolation of microbe**         |                                           |                                        |       |                 |         |
| Yes                              | 60 (70.6)                                 | 11 (64.7)                              | 71    | 0.232<sup>b</sup> | 0.630   |
| No                               | 25 (29.4)                                 | 6 (35.3)                               | 31    |                 |         |
| **Group of microbes**            |                                           |                                        |       |                 |         |
| Typical bacteria alone           | 28 (32.9)                                 | 5 (29.4)                               | 33    | 2.263<sup>c</sup> | 0.943   |
| Typical and atypical bacteria    | 5 (5.9)                                   | 2 (11.8)                               | 7     |                 |         |
| Typical bacteria and viruses     | 5 (5.9)                                   | 1 (5.9)                                | 6     |                 |         |
| Atypical bacteria only           | 10 (11.4)                                 | 1 (5.9)                                | 11    |                 |         |
| Atypical bacteria and Viruses    | 1 (1.2)                                   | 0 (0)                                  | 1     |                 |         |
| Viruses only                     | 11 (12.9)                                 | 1 (5.9)                                | 12    |                 |         |
| Fungi                            | 0 (0)                                     | 1 (5.9)                                | 1     |                 |         |
| None                             | 25 (29.4)                                 | 6 (35.3)                               | 31    |                 |         |

<sup>b</sup> = chi-square; <sup>c</sup> = yates corrected chi-square
Table 9: Multivariate logistic regression to determine the predictors of intra hospital mortality

| Variables                              | B    | p-value | OR   | 95% CI       |
|----------------------------------------|------|---------|------|--------------|
| Age of patient                         | 0.015| 0.486   | 1.015| 0.973 – 1.059|
| CURB-65 score ≥ 2                      | 2.672| **0.020**| 14.472| 1.523 – 137.562|
| Involvement of 2 or more lung lobes    | 0.170| 0.814   | 1.185| 0.286 – 4.909 |
| Presence of complications of CAP       | 3.254| **0.004**| 25.885| 2.788 – 240.337|
| Presence of hypoxaemia                 | 0.867| 0.239   | 2.381| 0.562 – 10.092 |
| Constant                               | -1.707| 0.271  | 0.181|              |

OR = odds ratio
95% CI = 95% confidence interval

Discussion

This study highlights the substantial burden of CAP in Ilorin, Nigeria, accounting for 5.9% of medical admissions in the hospital and occurring mostly in the elderly population. There was microbial detection in over two-thirds of our patients with gram-negative bacterial pathogens especially Klebsiella pneumoniae predominating from the isolates.

The preponderance of CAP in individuals older than 65 years supports findings from earlier observations that the disease is more common in elderly people. This can be explained by the higher risk of micro aspirations in elderly patients during sleep from depressed cough and glottis reflexes, the less efficient airway mucociliary clearance, the presence of comorbidities which serve as risk factors for CAP as well as the waning immunity in this unique population. There was also a slight female predominance which is in accordance with the report by Mbata et al that assessed the severity of CAP in the South Eastern region of Nigeria. The frequent and high intensity rainfall periods of May to August experienced the highest number of CAP cases which is in synchrony with a previously established relationship between cooler air temperature and increased CAP cases in the southern region of the country.

Furthermore, over three quarters of our patients had co-existing illnesses majority of which also doubled as risk factors for CAP. This included systemic hypertension, diabetes mellitus, cigarette smoking and sickle cell disease. The high number of co-morbid diseases surpassed related findings in previous retrospective studies on CAP in the country. The prospective nature of this study which helped circumvent issues relating to missing data may explain the higher number of comorbidities recorded.

Regarding the presenting symptoms of the patients, shortness of breath and cough dominated as the principal symptoms. This was in accordance with previous investigations on CAP by Le Bel et al and Muller et al but contrary to the report by Onyedum et al where fever and cough constituted the cardinal presenting symptoms of CAP. The challenge of recollecting the presence and sequence of symptoms, the varying cultural perception of the illness by the patients as well as the severity of the illness at presentation may have also contributed to the inconsistency of reported symptoms. Also, the subjective and potentially limiting nature of dyspnoea may have contributed to it being the most common presentation in our study.

We also observed that about half of our patients were admitted in hospital despite having a CURB-65 score of 0 or 1. This was largely due to a number of patients presenting with other markers of severity of CAP such as hypoxaemia and multilobe lung involvement. A significant number of patients also had background medical co-morbid illnesses which contributed to hospital admission. The patients with CURB-65 score of 4 were
The dominance of *Klebsiella pneumoniae* in this study but
nia in elderly patients 25, 26 and are also more common in
tive organisms are recognized to cause severe pneumo-
change in the epidemiological trend of aetiologic agents
tresses the need for further investigation into a possible
patients with co-morbid illnesses.27 Hence, the fact that
lower than figures observed by Lieberman et al 32 and
4,13,24 where *Streptococcus pneumoniae* was the main isolate.
The dominance of *Klebsiella pneumoniae* in this study but-
tresses the need for further investigation into a possible
tors in the epidemiological trend of aetiologic agents
of CAP in this environment. Additionally, gram nega-
tive organisms are recognized to cause severe pneumo-
ina in elderly patients 25, 26 and are also more common in
patients with co-morbid illnesses.27 Hence, the fact that
a third of our patients (33.3%) were over 65 years of
age and 86.3% of the patients had comorbidities could
have contributed to our discovery. Though *Haemophilus influenzae* is a recognized cause of CAP worldwide28 it
was not isolated in this survey as has equally been the
experience in previous studies in the country.3,4,29 The
fastidious nature of the pathogen in sputum culture
may have been responsible for its non-isolation.
Viruses were isolated in 18.6% of the subjects, either
solely or in combination with another bacterial patho-
gen with RSV being the predominant viral pathogen de-
tected. This figure was consistent with previous reports
by Mandell et al30 and Musher et al31. It was however
lower than figures observed by Lieberman et al32 and
Gadsby et al33 who had larger number of patients (183
and 323 patients respectively) and utilized more sophis-
ticated molecular techniques for isolation of pathogens
such as PCR. Also, the fact that the viral serologic assay
in this survey was limited to RSV and Influenza A virus
may account for the reduced number of viral agents
detected compared to the aforementioned studies in
which a broader range of viruses were sought.

Mixed or double pathogens were found in 13.7% of
subjects and this was consistent with observations
from a review article in Europe by Torres et al34 who
reported frequencies of CAP with mixed etiology to
vary between 0.4 – 19.9% across countries in Europe.
The finding is also in line with the observation by De
Roux et al35 who reported that mixed infections occur
in greater than 10% of patients admitted with CAP.
Overall, the finding of *Legionella pneumophilia* and RSV
as the leading atypical bacterium and virus respectively
in this study provides a strong template for further re-
search regarding atypical and viral CAP in Nigeria and
the West African sub-region; which up till now is largely
restricted to the developed world. This study also pro-
vides a guide as to the choice of empirical agent to be
employed prior to getting culture results. Individuals
demonstrating aforementioned risk factors for gram
negative pathogens may also benefit from use of third
generation cephalosporins instead of the widely used
penicillins and macrolides. However, it is clear from our
observations that penicillins are still advocated in cases
of hospitalized patients with gram-positive CAP.

About three quarters of the recruited patients were dis-
charged while the percentage mortality was 17.6%. The
percentage mortality of admitted patients was more
than that of previous reports from South East Nige-
ria3 and East Africa36 which reported mortality rates of
11.9% and 11% respectively. This may be due to the rel-
atively significant proportion of elderly patients in this
study. The percentage mortality in this study is however
less than the 26% reported by Tanimowo et al9 from pa-
ients managed in Osogbo, South Western Nigeria. This
may possibly be due to the fewer number of patients
with CAP (65) reviewed in their study.

**CURB - 65 scores ≥ 2** and the presence of complica-
tions of CAP were the identified independent predic-
tors of mortality. This is not surprising as the validat-
ed CURB-65 score is a recognized marker of disease
severity and predictor of mortality.37 The presence of
complications is also known to worsen disease severity
and confer worse prognosis.38

Regarding limitations of our study, the interpretation
of the results of may be affected by the fact that it was
conducted in a single centre with 102 patients. Also, we
did not capture antibiotic history outside that related
to the index illness which may also have affected the
spectrum of microbes isolated. However, this study still
significantly contributes to the body of knowledge for many reasons. Firstly, ours is a prospective study unlike the previous studies which were mainly retrospective data analyses of patients treated earlier and many of them involved even fewer patients. Furthermore, most of them were published more than 5 years ago and considering the fact they were retrospective analysis of patients treated earlier than the time of publication, they may not adequately reflect the current trends in adult patients with CAP. Another crucial reason in support of this work is the fact that, to the best of our knowledge, it is the first study in Nigeria and especially in the North Central region to test for atypical bacteria and viral pathogens in the aetiology of CAP among our adult population. Finally, our findings will serve as a template for further multicenter studies in the future; all of which will assist with formulating guidelines for treatment of CAP in our setting and in Africa as a whole.

**Conclusion**

CAP remains a significant cause of morbidity and mortality with admissions more common among the elderly population. Typical bacterial pathogens constitute the commonest cause of CAP in our setting with gram-negative pathogens, especially Klebsiella pneumoniae, predominating. While the carbapenems and third generation cephalosporins demonstrate good antibiotic susceptibility for the gram-negative pathogens, amoxicillin/clavulanic acid and cefuroxime still demonstrate good sensitivity for the gram-positive pathogens. These germane observations will serve as a guide to clinicians in our setting with regards to the empirical treatment of admitted patients with CAP.

**Funding**

None.

**Conflict of interest**

None declared.

**Acknowledgement**

We wish to acknowledge the immense contributions of all the resident doctors in the department of Medicine of the hospital who notified the team whenever patients with community acquired pneumonia were admitted. We also greatly appreciate all the patients who gave consent to participate in the study. The huge efforts of Dr Taiye Balogun who assisted with some aspects of the data analysis is also well recognized.

**References**

1. File TM, Jr., Marrie TJ. Burden of community-acquired pneumonia in North American adults. *Postgrad Med.* 2010;122(2):130-141. doi: 10.3810/pgm.2010.03.2130.
2. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet.* 2012;380(9859):2095-2128. doi: 10.1016/S0140-6736(12)61728-0.
3. Onyedum CC, Chukwuka JC. Admission profile and management of community acquired pneumonia in Nigeria: 5-year experience in a tertiary hospital. *Respir Med.* 2011;105(2):298-302. doi: 10.1016/j.rmed.2010.11.003.
4. Fiberesima FP, Onwuchekwa AC. Community acquired pneumonia in Port Harcourt Rivers State of Nigeria. *Centr Afr J Med.* 2008;54(1-4):1-8. PMID: 21648126.
5. Umoh VA, Ateh JT, Okpa HO, Effa E. The pattern of respiratory disease morbidity and mortality in a tertiary hospital in southern-eastern Nigeria. *Palm Med.* 2013:581973. doi: 10.1155/2013/581973 (Accessed 1st March, 2020)
6. Desalu OO, Oluwafemi JA, Ojo O. Respiratory diseases morbidity and mortality among adults attending a tertiary hospital in Nigeria. *J brasileiro de pneumologia.* 2009;35(8):745-752. doi: 10.1590/S1806-37132009000800005.
7. Mbata GC, Onyedum CC, Onwubere BJ, Aguwa EN. Comparison of two predictive rules for assessing severity of community acquired pneumonia. *Afr J Respir Med.* 2014;10(1):10-14.
8. Nwosu C, Anisuba B. A hospital study of adults with CAP 11-clinical course and complications. *Orient J Med.* 1991;3:196-199 PubMed .
9. Tanimowo MO. Mortality predictors in community-acquired pneumonia. *Niger J Clin Pract.* 2009;12(3):298 PubMed -301. PMID: 19803030.
10. Scott JA, Adegbola R, Gordon SB. Pneumonia in adults. *Principles of Medicine in Africa.* 4th edition. 2012: 264-276.
11. Ruuskanen O, Lahti E, Jennings LC, Murdoch DR. Viral pneumonia. *Lancet.* 2011;377(9773):1264 PubMed -1275. doi: 10.1016/S0140-6736(10)61459-6.
12. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. *Thorax.* 2012;67 (1):71 PubMed -79. doi: 10.1136/thx.2009.129502.
13. Iroezindu MO, Chima EI, Isiguzo GC, Mbata
GC, Onyedum CC, Onyedibe KI, et al. Sputum bacteriology and antibiotic sensitivity patterns of community-acquired pneumonia in hospitalized adult patients in Nigeria: a 5-year multicentre retrospective study. *Scand J Infect Dis.* 2014;46(12):875-887. doi: 10.3109/00365548.2014.954263.

14. Egbagbe E, Mordi R. Aetiology of lower respiratory tract infection in Benin City, Nigeria. *J Biomed Sci.* 2006;5(2):22-27. doi: 10.4314/jmbvr.v5i2.10687.

15. Okesola AO, Ige OM. Trends in bacterial pathogens of lower respiratory tract infections. *Indian J Chest Dis Allied Sci.* 2008;50(3):269-272. PMID: 18630792.

16. Bartlett JG, Dowell SF, Mandell LA, File Jr TM, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. *Clin Infect Dis.* 2000;31(2):347-382. doi: 10.1086/313954.

17. Ramirez JA, Wiemken TL, Peyrani P, et al. Adults Hospitalized With Pneumonia in the United States: Incidence, Epidemiology, and Mortality. *Clin Infect Dis.* 2017; 65:1806-1812. doi: 10.1093/cid/cix647.

18. Jain S, Self WH, Wunderink RG, et al; CDC EPIC Study Team. Community acquired pneumonia requiring hospitalization among U.S. adults. *N Engl J Med* 2015; 373 (5):415-427. doi: 10.1056/NEJMoai1500245.

19. Oluleye A, Akinbobola A. Malaria and pneumonia occurrence in Lagos, Nigeria: Role in temperature and rainfall. *Afr J Environ Sci Technol.* 2010, 4(8), 506-516. doi: 10.5897/AJEST10.109.

20. Le Bel J, Hausfater P, Chenevier-Gobeaux C, Blanc FX, Benjoar M, Ficko C, et al. Diagnostic accuracy of C-reactive protein and procalcitonin in suspected community-acquired pneumonia adults visiting emergency department and having a systematic thoracic CT scan. *Crit Care.* 2015;19:366. doi: 10.1186/s13054-015-1083-6.

21. Muller F, Christ-Crain M, Bregenzer T, Krause M, Zimmerli W, Mueller B, et al. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. *Chest.* 2010;138(1):121-129. doi: 10.1378/chest.09-2920.

22. Egbe CA, Ndikwere C, Omoriege R. Microbiology of Lower Respiratory Tract Infections in Benin City, Nigeria. *Malays J Med Sci.* 2011;18(2):27-31. PMID: 22135583.

23. Ojo-Bola O, Oluyege A. Antibiotics resistance of bacteria associated with Pneumonia in HIV/AIDS patients in Nigeria. *Am J Infect Dis Microbiol.* 2014;2(6):138-144. doi: 10.12691/ajidm-2-6-1.

24. Iliyasu G, Habib AG, Mohammed AB, Borodo MM. Epidemiology and Clinical Outcomes of Community Acquired Pneumococcal Infection in North-West Nigeria. *Sub-Saharan Afr J Med.* 2015;2(2):79-84. doi: 10.4103/2384-5147.

25. Leroy O, Sante C, Beuscart C, Georges H, Guery B, Jacquier JM, et al. A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit. *Intensive Care Med.* 1995;21(1):24-31. doi: 10.1007/BF02425150.

26. Vila-Corcoles A, Ochoa-Gondar O, Rodriguez-Blanco T, Raga-Luria X, Gomez-Bertomeu F. Epidemiology of community-acquired pneumonia in older adults: a population-based study. *Respir Med.* 2009;103(2):309-316. doi: 10.1016/j.rmed.2008.08.006.

27. Arancibia F, Bauer TT, Ewig S, Mensa J, Gonzalez J, Niederman MS, et al. Community-acquired pneumonia due to gram-negative bacteria and *Pseudomonas aeruginosa*: incidence, risk, and prognosis. *Arch Intern Med.* 2002;162(16):1849-1858. doi:10.1001/ archinte.162.16.1849.

28. Musher DM, Thorner AR. Community-acquired pneumonia. *N Engl J Med* 2014; 371:1619-1628. doi: 10.1056/NEJMra1312885.

29. Sofowora EO, Onadeko BO. Complications and prognostic factors in pneumonia among Nigerians. *Nig Med J.* 1973;3:144-145. PMID: 16366348.

30. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. *Clin Infect Dis.* 2007;44(Supplement 2):S27-S72. doi: 10.1086/511159.

31. Musher DM, Roig IL, Cazares G, Stage CE, Logan N, Safar H. Can an etiologic agent be identified in adults who are hospitalized for community-acquired pneumonia: results of a one-year study. *J Infect.* 2013;67(1):11-18. doi: 10.1016/j.jinf.2013.03.003.

32. Lieberman D, Shimoni A, Shemer-Avni Y, Kerennao A, Shtainberg R, Lieberman D. Respiratory viruses in adults with community-acquired pneumonia. *Chest.* 2010;138(4):811-816. doi: 10.1378/chest.09-2717.

33. Gadsby NJ, Russell CD, McHugh MP, Mark H, Conway Morris A, Laurenson IF, et al. Comprehensive Molecular Testing for Respiratory Pathogens in Community-Acquired Pneumonia. *Clin Infect Dis.* 2016;62(7):817-823. doi: 10.1093/cid/civ1241.

34. Torres A, Blasi F, Peetersmans WE, Viegi G, Welte T. The actiology and antibiotic management of community-acquired pneumonia in adults in Europe: a literature review. *Eur J Clin Microbiol Infect Dis.* 2014;33(7):1065-1079. doi: 10.1007/s10096-014-2067-1.

35. De Roux A, Ewig S, Garcia E, Marcos MA, Mensa...
36. Aderaye G. Community acquired pneumonia in adults in Addis Abeba: etiologic agents, clinical and radiographic presentation. *Ethiop Med J*. 1994;32(2):115-123. PMID: 8033877.

37. Lim WS, Van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. *Thorax*. 2003. 58 (5): 377–382. doi: 10.1136/thorax.58.5.377.

38. Restrepo MI, Faverio P, Anzueto A. Long-term prognosis in community-acquired pneumonia. *Curr Opin Infect Dis*. 2013;26(2):151-158. doi:10.1097/QCO.0b013e32835ebc6d